Navigation Links
Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement
Date:11/7/2007

of Public Security ("MPS") searched multiple businesses and residential locations, seized more than $7 million in assets, and confiscated over 290,000 counterfeit software CDs and Certificates of Authenticity. Microsoft publicly stated that the MPS and FBI dismantled a criminal syndicate "believed to be the largest of its kind in the world," responsible for distributing more than $2 billion in counterfeit Microsoft software.

The Department also led an initiative with members of the G8 industrialized nations to develop a framework for cooperation on intellectual property crime investigations. In November 2006, all members of the G8's Lyon-Roma anti-crime group approved the "Principles and Recommendations for Cooperative Investigation and Prosecution of Serious and Organized Intellectual Property Rights Crime," which set forth a foundation for future cooperation on criminal IP enforcement among the G8 members. In June 2007, the G8 Leaders endorsed the Principles and Recommendations at their annual Summit in Munich, Germany.

-- The Department's Civil Enforcement Efforts

The Department's Civil Division has supported the enforcement of IP rights by owners of those rights principally through participation in private law suits as amicus. Since October 2004, the Department has filed 18 amicus briefs in 14 Supreme Court cases, and numerous other cases in the lower courts. Recently, in three important patent cases -- Microsoft v. AT&T Corp, KSR International v. Teleflex, and MedImmune v. Genentech -- the Supreme Court adopted the arguments of the Department recognizing the important balance between intellectual property rights and the overarching aim of spurring innovation. In addition, the Civil Division's Office of Consumer Litigation ("OCL") handles criminal and civil cases involving intellectual property laws that protect public health and safety, particularly in the regulation of drugs by the Food and Drug Administration. To maintain the high quality
'/>"/>

SOURCE U.S. Department of Justice
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Schwarzenegger Signs Bill to Remove Written Informed Consent for HIV Testing; "Most Important Change in Public HIV/AIDS Policy in Years," Says AHF
2. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
3. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
4. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
5. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
6. Statement by Oscar S. Wyatt, Jr.
7. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
8. Pelosi Statement on Proposed Entitlement Task Force
9. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
10. Statement on House/Senate Agreement on SCHIP Legislation
11. Statement from the Alliance for Quality Nursing Home Care
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 2Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 3Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 4Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 5Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 6Health News:Heart Hormones Beat Back Cancers in Mice 2Health News:Heart Hormones Beat Back Cancers in Mice 3Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 2Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 3Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 4Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 5Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 6Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 2Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 3Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 4Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 5Health News:Plastic Surgeon Joins Established Practice 2
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 1Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 2Midlife Heart Risk Factors Linked to Later Dementia 53613 1Midlife Heart Risk Factors Linked to Later Dementia 53613 2Midlife Heart Risk Factors Linked to Later Dementia 53613 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4